66th ASH Annual Meeting: DDX41-Mediated Malignancies

Symposia: Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure Scientific Workshops

Room 6CF (San Diego Convention Center)

Moderators:

Satish Nandakumar, MBBS, PhD, Albert Einstein College of Medicine and Andres Jerez, University Hospital Vall d´Hebron

Disclosures:

Jerez: Astrazeneca: Research Funding.

This session will focus on the emerging molecular mechanisms by which deleterious germline DDX41 variants lead to hematopoietic malignancies (HMs).

Moderator Introduction

Satish Nandakumar, MBBS, PhD

Albert Einstein College of Medicine, New York, NY

DDX41 Dissolves G-Quadruplexes to Maintain Erythroid Genomic Integrity and Prevent Cgas Activation-Induced Erythropoiesis Dysfunction

Honghao Bi, PhD

Northwestern University, Chicago, IL

Pathogenic Mechanisms of DDX41 Mutations in the Development of Myeloid Malignancies

Ayana Kon, MD, PhD

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Hematology and Tumor Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Division of Stem Cell and Genome Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Investigating the Role of the R525H DDX41 Somatic Variant in the Context of DDX41 Mutant Germline Predisposition Syndrome

Ludovica Marando, MD, PhD

Mayo Clinic, Rochester; University of Cambridge, Cambridge, United Kingdom

Yael Kusne, MD, PhD

Mayo Clinic, Phoenix, AZ

DDX41 in Real Life

Marie Sebert, MD, PhD

Saint-Louis Hospital, Paris, France

Characterizing Dead-Box ATP-Dependent RNA Helicase 41 (DDX41) Germline Variants in Hereditary Myeloid Neoplasms

Kirsten Gronbaek, MD, PhD, PR

Rigshospitalet, University of Copenhagen, Copenhagen N, Denmark; Rigshospitalet, University of Copenhagen, Kirsten Grønbæk, Copenhagen N, Denmark

Germline/Somatic Genomic Constellations Predict Outcomes in DDX41-Mutant Myeloid Neoplasia